Sept. 25, 2008
UI first in Iowa to enroll people for new heart failure research study
The University of Iowa Heart and Vascular Center's Cardiomyopathy Treatment Program is the first site in Iowa to enroll participants into a clinical trial to evaluate the benefits of a wireless pressure sensor for heart failure. This sensor is being studied to see if it will reduce the number of hospitalizations for people with heart failure.
The trial is being directed by Barry Cabuay, M.D., principal investigator and a heart failure and transplant specialist with the UI Heart and Vascular Center's Cardiomyopathy Treatment Program. The first two participants at UI Hospitals and Clinics were enrolled in April without complication. Approximately 550 participants nationwide will be enrolled in this trial.
Additional participants are sought for this trial, which is investigating the safety and effectiveness of the CardioMEMS Heart Failure Pressure Measurement System. Eligible participants must have a history of heart failure and have had a heart failure-related hospitalization in the past 12 months.
The wireless heart failure sensor is a proprietary miniature device designed and developed by CardioMEMS, Inc. The sensor is implanted into the participant's pulmonary artery using a simple, catheter-based procedure, which is similar to a heart catheterization. At home, participants transmit pulmonary artery pressure measurements wirelessly by laying on a specialized soft sensor pad.
The pressure data is immediately transmitted to a computer database and is available for review on a secure Web site by the physician. The data, as well as the pressure waveform, is available to the physician by any computer or by a PDA. The trial will study the hypothesis that directly measured pulmonary artery pressures will improve heart failure management and thus reduce the need for heart failure hospitalizations.
The UI Cardiomyopathy Treatment Program is currently participating in more than 20 clinical trials, involving options for people with heart failure, heart transplant needs, and pulmonary hypertension.
"We are excited to be the only center in Iowa to offer this novel device, placed through a minimally invasive procedure," Cabuay said. "We hope the information gained from this device will enhance heart failure management in this complicated patient population."
Jay Yadav, M.D., chairman and CEO of CardioMEMS, Inc., commented, "CardioMEMS is very pleased to be collaborating with Dr. Cabuay and his colleagues at University of Iowa Health Care on this exciting clinical trial."
CardioMEMS, located in Atlanta, Ga., is a privately held medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Learn more about the company at http://www.cardiomems.com.
For more information, contact the UI Cardiomyopathy Treatment Program at 319-356-1028 and ask for Barry Cabuay or Cynthia Larew or visit online at http://www.uihealthcare.com/heartfailure.
NOTE TO EDITORS: This release includes information provided by CardioMEMS.
STORY SOURCE: University of Iowa Health Science Relations, 5137 Westlawn, Iowa City, Iowa 52242-1178
MEDIA CONTACT: Becky Soglin, 319-335-6660, email@example.com (Contact listed is for media only; potential study participants, please see contact info in news release)